keyword
MENU ▼
Read by QxMD icon Read
search

Relapsed diffuse large b cell lymphoma

keyword
https://www.readbyqxmd.com/read/29786758/long-term-complete-remission-following-tandem-autologous-stem-cell-transplantation-and-consolidative-radiotherapy-for-refractory-mediastinal-gray-zone-lymphoma
#1
Koji Takaishi, Tomoya Muto, Naoya Mimura, Jun Takiguchi, Yuhei Nagao, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Shio Mitsukawa, Masahiro Takeuchi, Chikako Ohwada, Satoshi Ota, Tohru Iseki, Chiaki Nakaseko, Emiko Sakaida
Mediastinal gray zone lymphoma (MGZL) is a provisional entity with intermediate features between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma. Outcomes for patients with MGZL are reportedly poorer than those for patients with cHL or primary mediastinal large B-cell lymphoma. Additionally, no standard management guidelines for patients with MGZL are available, primarily due to its recent identification, rarity, and challenges in diagnosis. Although recent several studies have suggested dose-adjusted EPOCH-R (etoposide, doxorubicin, vincristine, cyclophosphamide, prednisolone, and rituximab) may improve outcomes in patients with MGZL, numerous patients still suffer from relapsed/refractory MGZL, and the optimal management for such patients remains uncertain...
May 21, 2018: International Journal of Hematology
https://www.readbyqxmd.com/read/29779319/-comprehensive-geriatric-assessment-can-predict-the-clinical-outcomes-of-elderly-patients-with-diffuse-large-b-cell-lymphoma-in-china
#2
C L Zhang, R Feng, J T Li, Y Tian, T Wang, H Liu
Objective: To validate comprehensive geriatric assessment (CGA) system in Chinese elderly diffuse large B cell lymphoma (DLBCL) patients. Methods: Patients ≥ 65 years of age who had been diagnosed with de novo DLBCL were screened for eligibility ( n =99). CGA was performed during staging procedures through application of the following instruments: age, comorbidity score according to the Cumulative Illness Rating Score for Geriatrics(CIRS-G), activities of daily living (ADL), and instrumental activities of daily living (IADL)...
April 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29779211/cutaneous-sarcoidosis-a-new-subset-in-the-spectrum-of-paraneoplastic-dermatoses
#3
M El-Khalawany, A Mosbeh, S Aboeldahab, S Ali
BACKGROUND: Sarcoidosis is a well-described disease that can be associated with various malignancies; however, this correlation is still not fully clarified. AIM: To determine the clinical and histological features, demographic characteristics, and prognosis of patients diagnosed with paraneoplastic sarcoidosis (PS). METHODS: This observational cohort prospective study included all patients diagnosed as cutaneous sarcoidosis. All patients were monitored for therapeutic response, prognosis, and any associated diseases or malignancies...
May 20, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29777009/feasibility-of-cxcr4-directed-radioligand-therapy-in-advanced-diffuse-large-b-cell-lymphoma
#4
Constantin Lapa, Heribert Hänscheid, Malte Kircher, Andreas Schirbel, Gerd Wunderlich, Rudolf Werner, Samuel Samnick, Jörg Kotzerke, Hermann Einsele, Andreas Buck, Hans-Jürgen Wester, Götz Ulrich Grigoleit
We have recently reported on our experience with C-X-C-motif chemokine receptor 4- (CXCR4-) directed radioligand therapy (RLT) in multiple myeloma and acute leukemia. Methods: Six patients with heavily pre-treated relapsed diffuse large B cell lymphoma (DLBCL) (3 males, 3 females; aged, 54±8 years) underwent CXCR4-directed RLT in combination with conditioning chemotherapy and allogeneic stem cell transplantation (SCT). In 2 patients, radioimmunotherapy (RIT) targeting CD20 or CD66 was added to enhance anti-lymphoma activity...
May 18, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29771253/axicabtagene-ciloleucel-for-the-treatment-of-relapsed-refractory-b-cell-non-hodgkin-s-lymphomas
#5
P Sharma, G T King, S S Shinde, E Purev, A Jimeno
B-cell non-Hodgkin's lymphomas are the most common hematological malignancies, which despite improvements in chemo-immunotherapy, carry a uniformly poor prognosis in the relapsed/refractory setting. CD19 is an antigen expressed on the surface of most malignancies arising from the B cells, and adoptive transfer of anti-CD19 chimeric antigen receptor (CAR)-expressing T cells has been shown to be effective in treating these B-cell malignancies. Axicabtagene ciloleucel (axi-cel, KTE-C19) is an autologous anti-CD19 CAR T-cell therapy which has shown high overall response rates and a manageable safety profile in patients with relapsed or refractory B-cell malignancies who lack effective and curative treatment options...
March 2018: Drugs of Today
https://www.readbyqxmd.com/read/29770496/long-term-survival-and-loss-in-expectancy-of-life-in-a-population-based-cohort-of-7114-patients-with-diffuse-large-b-cell-lymphoma
#6
Sara Ekberg, Mats Jerkeman, Per-Ola Andersson, Gunilla Enblad, Björn E Wahlin, Sverker Hasselblom, Therese M Andersson, Sandra Eloranta, Karin E Smedby
Survival has improved among patients with diffuse large B-cell lymphoma (DLBCL) with the addition of anti-CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population-based level. Patients diagnosed with DLBCL 2000-2013 (N=7114) were identified through the Swedish Lymphoma Registry and classified according to the age-adjusted International Prognostic Index (aaIPI).The novel measure LEL is the difference between remaining life years among patients and the general population and was predicted using flexible parametric models from diagnosis and among 2-year survivors, by age and sex...
May 17, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29767447/expression-of-ribosomal-and-actin-network-proteins-and-immunochemotherapy-resistance-in-diffuse-large-b-cell-lymphoma-patients
#7
Susanne Bram Ednersson, Martin Stenson, Mimmie Stern, Gunilla Enblad, Henrik Fagman, Herman Nilsson-Ehle, Sverker Hasselblom, Per-Ola Andersson
Diffuse large B cell lymphoma (DLBCL) patients with early relapse or refractory disease have a very poor outcome. Immunochemotherapy resistance will probably, also in the era of targeted drugs, remain the major cause of treatment failure. We used proteomic mass spectrometry to analyse the global protein expression of micro-dissected formalin-fixed paraffin-embedded tumour tissues from 97 DLBCL patients: 44 with primary refractory disease or relapse within 1 year from diagnosis (REF/REL), and 53 who were progression-free more than 5 years after diagnosis (CURED)...
May 16, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29752199/gemcitabine-oxaliplatin-plus-rituximab-r-gemox-as-first-line-treatment-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-single-arm-open-label-phase-2-trial
#8
Qiu-Dan Shen, Hua-Yuan Zhu, Li Wang, Lei Fan, Jin-Hua Liang, Lei Cao, Wei Wu, Yi Xia, Jian-Yong Li, Wei Xu
BACKGROUND: The combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx) has shown high efficacy with a low toxicity profile in elderly patients with relapsed and refractory diffuse large B-cell lymphoma. We aimed to evaluate the efficacy, safety, and feasibility of the R-GemOx regimen as a first-line treatment in elderly patients with diffuse large B-cell lymphoma. METHODS: In this single-arm, open-label, phase 2 clinical trial, we enrolled patients with previously untreated, histologically confirmed, CD20-positive diffuse large B-cell lymphoma, aged 70 years or older, or aged 60-69 years with an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or greater...
May 8, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29748443/a-phase-2-multicenter-study-of-the-anti-cd19-antibody-drug-conjugate-coltuximab-ravtansine-sar3419-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-previously-treated-with-rituximab-based-immunotherapy
#9
Marek Trněný, Gregor Verhoef, Martin Js Dyer, Dina Ben Yehuda, Caterina Patti, Miguel Canales, Andrés Lopez, Farrukh T Awan, Paul G Montgomery, Andrea Janikova, Anna M Barbui, Kazimierz Sulek, Maria J Terol, John Radford, Anna Guidetti, Massimo Di Nicola, Laure Siraudin, Laurence Hatteville, Sandrine Schwab, Corina Oprea, Alessandro M Gianni
This phase 2, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented (de novo or transformed) relapsed or refractory diffuse large B-cell lymphoma who had previously received rituximab containing immuno-chemotherapy. Patients had received a median of 2.0 (range 0-9) prior treatment regimens for diffuse large B-cell lymphoma and almost half (45.9%) had bulky disease (≥ lesion >5 cm) at trial entry...
May 10, 2018: Haematologica
https://www.readbyqxmd.com/read/29741421/treatment-of-newly-diagnosed-primary-central-nervous-system-lymphoma-current-and-emerging-therapies
#10
Tarsheen K Sethi, Nishitha M Reddy
Primary central nervous lymphoma (PCNSL) is a rare extra-nodal subtype of non-Hodgkin lymphoma and most cases are of diffuse large B-cell lymphoma histology with an aggressive presentation. The treatment of PCNSL has evolved over the years from radiation alone to multi-agent chemotherapy with the goal of minimizing long-term toxicity. Recent studies have evaluated autologous stem cell transplant as consolidation in eligible patients with success. The prognosis of relapsed disease remains poor and hence the emphasis is on effective and less toxic frontline strategies...
May 9, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29725882/a-rare-case-of-a-spontaneously-ruptured-secondary-hepatic-malignant-lymphoma
#11
Ko Oshita, Toshiyuki Itamoto, Akihiko Oshita, Hideki Nakahara, Takashi Nishisaka
BACKGROUND: Although secondary liver involvement of the lymphoma is common and occurs in 50% of patients with non-Hodgkin's lymphoma, liver tumor rupture in malignant lymphoma is extremely rare. We report a case of a spontaneously ruptured secondary liver involvement of non-Hodgkin's lymphoma that was successfully treated with transcatheter arterial embolization (TAE) to obtain hemostasis, and subsequent hepatectomy and systemic chemotherapy. To the best of our knowledge, this is only the second reported case of a ruptured hepatic lymphoma...
May 3, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29725548/a-case-report-of-nongerminal-center-b-cell-type-diffuse-large-b-cell-lymphoma-treated-to-complete-response-with-rituximab-and-ibrutinib
#12
Geoffrey Shouse, Miemie Thinn
Diffuse large B-cell lymphoma (DLBCL) is a molecularly heterogeneous disease consisting of different subtypes with varying clinical behaviors. For example, the activated B-cell-like (ABC) type of DLBCL has lower cure rates with traditional chemotherapy regimens. The molecular pathway promoting tumorigenic growth of the ABC type includes a dependence on intracellular signaling by Bruton's agammaglobulinemia tyrosine kinase (BTK). This specific pathway has led to the investigation of the utility of ibrutinib in treatment of this type of lymphoma at relapse or in combination with standard chemotherapy...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29722657/patterns-of-failure-in-patients-with-double-hit-or-double-expressor-lymphomas-implications-for-radiation-therapy
#13
Vasu Tumati, Lakshya Trivedi, Hsiao-Ching Li, Prapti Patel, Pier P Scaglioni, Madhuri Vusirikala, Navid Sadeghi, Syed Rizvi, Weina Chen, Jason Wachsmann, Robert Collins, Neil B Desai
PURPOSE: Lymphomas with MYC and either BLC2 or BCL6 rearrangements or MYC and BCL-2 protein overexpression, classified as double-hit (DHL) or double-expressor (DEL) lymphomas, respectively, are associated with poorer response to standard immunochemotherapy. Optimal therapy is not clear, and little information exists on the contribution of consolidative radiation therapy in these patients. This study describes the patterns of failure of DHL/DEL in relation to initial sites of disease and indications for radiation therapy in unselected diffuse large B-cell lymphoma (DLBCL)...
April 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29722049/refractory-diffuse-large-b-cell-lymphoma-after-first-line-immuno-ct-treatment-options-and-outcomes
#14
Lauriane Filliatre-Clement, Delphine Maucort-Boulch, Estelle Bourbon, Lionel Karlin, Violaine Safar, Emmanuel Bachy, Pierre Sesques, Emmanuelle Ferrant, Fadela Bouafia, Anne Lazareth, Dana Ghergus, Bertrand Coiffier, Alexandra Traverse Glehen, Gilles Salles, Hervé Ghesquieres, Clémentine Sarkozy
In the rituximab era, one-third of diffuse large B-cell lymphoma patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy. Optimal management remains an unmet medical need. The aim of this study was to report the outcomes of a cohort of refractory patients according to their patterns of refractoriness and the type of salvage option. We performed a retrospective analysis, which included 104 diffuse large B-cell lymphoma patients treated at Lyon Sud University Hospital (2002-2017) who presented with refractory disease...
May 2, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/29716630/serum-mir-22-as-potential-non-invasive-predictor-of-poor-clinical-outcome-in-newly-diagnosed-uniformly-treated-patients-with-diffuse-large-b-cell-lymphoma-an-explorative-pilot-study
#15
Francesco Marchesi, Giulia Regazzo, Francesca Palombi, Irene Terrenato, Andrea Sacconi, Manuela Spagnuolo, Sara Donzelli, Mirella Marino, Cristiana Ercolani, Anna Di Benedetto, Giovanni Blandino, Gennaro Ciliberto, Andrea Mengarelli, Maria Giulia Rizzo
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of tumors, with aggressive clinical course that renders prognostication and choice of treatment strategy difficult. Chemo-immunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) is the current first-line treatment. MicroRNAs (miRNAs) are under investigation as novel diagnostic and prognostic biomarkers in several malignancies, including malignant lymphomas. While tissue miRNAs in DLBCL patients have been extensively studied as biomarkers, only few reports to date have evaluated the role of circulating/serum miRNAs as potential prognostic factors...
May 2, 2018: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/29703034/usefulness-of-18f-fdg-pet-ct-for-evaluating-response-of-ocular-adnexal-lymphoma-to-treatment
#16
Hayahiko Fujii, Hiroaki Tanaka, Yohei Nomoto, Naoki Harata, Sayako Oota, Jun Isogai, Katsuya Yoshida
The purpose of this study was to investigate the efficacy of F-fluoro-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for evaluating the ocular adnexal lymphoma treatment responses.We retrospectively reviewed data for 9 histologically confirmed cases of malignant lymphoma. All patients had at least one ocular adnexal tumor site and underwent FDG PET/CT before and after treatment. Patients' histological disease subtypes included diffuse large B-cell lymphoma (n = 3), mucosa-associated lymphoid tissue lymphoma (n = 2), follicular lymphoma (n = 1), NK/T-cell lymphoma (n = 1), lymphoplasmacytic lymphoma (n = 1), and Hodgkin lymphoma (n = 1)...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29697005/primary-breast-diffuse-large-b-cell-lymphoma-treatment-strategies-and-patterns-of-failure
#17
Ethan B Ludmir, Sarah A Milgrom, Chelsea C Pinnix, Jillian R Gunther, Jason Westin, Yasuhiro Oki, Luis E Fayad, L Jeffrey Medeiros, Bouthaina S Dabaja, Loretta J Nastoupil
Treatment strategies and outcomes were assessed in 25 patients with primary breast diffuse large B-cell lymphoma (PB-DLBCL) treated between 1995 and 2016. We specifically investigated the timing of recurrence, and the roles of radiotherapy (RT) and central nervous system prophylaxis (CNS PPX). Fifty-two percent of patients received RT, and 28% received CNS PPX. Fourteen patients (56%) experienced recurrence, with 76% of relapses occurring ≥24 months after diagnosis, in contrast to reports supporting the use of 24-month event-free survival as a surrogate endpoint in the general DLBCL population...
April 26, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29695516/phase-1-study-of-the-pi3k%C3%AE-inhibitor-incb040093-%C3%A2-jak1-inhibitor-itacitinib-in-relapsed-refractory-b-cell-lymphoma
#18
Tycel J Phillips, Andres Forero-Torres, Taimur Sher, Catherine S Diefenbach, Patrick Johnston, Moshe Talpaz, Jennifer Pulini, Li Zhou, Peggy Scherle, Xuejun Chen, Paul M Barr
Because both phosphatidylinositol 3-kinase δ (PI3Kδ) and Janus kinase (JAK)-signal transducer and activator of transcription pathways contribute to tumor cell proliferation and survival in B-cell malignancies, their simultaneous inhibition may provide synergistic treatment efficacy. This phase 1 dose-escalation/expansion study assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of INCB040093, a selective PI3Kδ inhibitor, as monotherapy or combined with itacitinib (formerly INCB039110), a selective JAK1 inhibitor, in adult patients with relapsed or refractory (R/R) B-cell lymphomas...
April 25, 2018: Blood
https://www.readbyqxmd.com/read/29665940/-advances-in-the-molecular-diagnosis-and-therapy-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-review
#19
Yi Wang, Bing Xia, Yi-Zhuo Zhang
Diffuse large B-cell lymphoma (DLBCL) is biologically aggressive and most common pathological type of non-Hodgkin's lymphoma (NHL), and about one-third of these patients are refractory or relapsed ultimately. Based on the molecular heterogeneity, DLBCL can be divided into 3 main molecular subtypes: germinal center B-cell like (GCB), activated B-cell like (ABC) and primary mediastinal B-cell lymphoma (PMBL). Arising from B cells at distinct stages of differentiation, these subtypes are also diverse in mechanisms of oncogenic activation...
April 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29660176/the-role-of-radiotherapy-as-salvage-and-or-consolidation-treatment-in-relapsed-refractory-and-high-risk-diffuse-large-b-cell-lymphoma
#20
Eric Grignano, Jérémy Laurent, Bénédicte Deau, Barbara Burroni, Didier Bouscary, Youlia M Kirova
OBJECTIVE: Many salvage therapies have been proposed for relapsed/refractory (R/R) diffuse large B-cell lymphomas or for consolidation in the case of suboptimal response. Radiotherapy (RT) is one modality of salvage therapy, but its place is currently not well defined. METHOD: This paper reports a retrospective review of patients receiving unplanned radiotherapy for R/R diffuse large B-cell lymphoma (DLBCL) or primary mediastinal B-cell lymphoma (PMBCL), or as consolidation therapy after second line chemotherapy, treated in our hospital...
April 16, 2018: European Journal of Haematology
keyword
keyword
101126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"